Must we screen for hemochromatosis ? Critical appraisal of literature;Faut-il depister I'homochromatose ? Analyse critique de la litterature

Revue d'Epidemiologie et de Sante Publique

Volumn 45, Issue 4, 1997, Pages 315-327

  Charvet Protat, S ^a   Yaouanq, J ^b   Fleurette, F ^a  

^a ANDEM   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Acceptability; Economic evaluation; Feasibility; Individual preferences; Screening program

Indexed keywords

ARTICLE; ECONOMIC EVALUATION; HEALTH CARE POLICY; HEMOCHROMATOSIS; HUMAN; SCREENING TEST; TREATMENT OUTCOME; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE PLANNING; HEALTH SURVEY; INCIDENCE; MALE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; MORBIDITY; PREVALENCE; PUBLIC HEALTH; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARD;

COMMUNITY HEALTH PLANNING; COST-BENEFIT ANALYSIS; FEMALE; HEMOCHROMATOSIS; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; MORBIDITY; POPULATION SURVEILLANCE; PREVALENCE; PUBLIC HEALTH; SENSITIVITY AND SPECIFICITY;

EID: 0030886650     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Simon M, Bourel M, Genetet B, Fauchet R. Idiopathic hemochromatosis. Demonstration of recessive inheritance and early detection by HLA typing. N Engl J Med 1977 ; 297 : 1017-21.
2. Simon M. Génétique et épidémiologie de l'hémochromatose idiopathique. Ann Méd Interne 1987 ; 138(Suppl) : 36-43.
3. Le Gall JY, David V, Yaouanq J et al. Génétique moléculaire de l'hémochromatose. Bull Acad Natl Med 1993 ; 177 : 187-201.
4. Feder JN, Gnirke A, Thomas W et al. A novel MHC class-I like gene is mutated in patients with hereditary hemochromatosis. Nature Genet 1996 ; 13 : 399-408.
5. Edwards CQ, Cartwright GE, Skolnick MH, Amos DB. Homozygosity for hemochromatosis : clinical manisfestations. Ann Intern Med 1980 ; 93 : 519-25.
6. Fargion S, Mandelli C, Piperno A et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatotogy 1992 ; 15 : 655-9.
7. Milman N. Hereditary haemochromatosis in Denmark 1950-1985. Clinical, biochemical and histological features in 179 patients and 13 preclinical cases. Dan Med Bull 1991 ; 38 : 385-93.
8. Adams PC, Kertesz AE, Valberg LS. Clinical presentation of hemochromatosis: a changing scene. Am J Med 1991 ; 90 : 445-9.
9. Aellen P, Guerne PA, Zenagui D, Vischer TL. L'arthropathie de l'hémochromatose : manifestation souvent inaugurale de la maladie. Schweiz Med Wochenschr 1992 ; 122 : 842-9.
10. Hamilton EBD, Bomford AB, Laws JW, Williams R. The natural history of arthritis in idiopathic haemochromatosis: progression of the clinical and radiological features over ten years. Q J Med 1981 ; 50 : 321-9.
11. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985 ; 313 : 1256-62.
12. Velati C, Piperno A, Fargion S, Colombo S, Fiorelli G. Prevalence of idiopathic hemochromatosis in Italy : study of 1301 blood donors. Haematologia 1990 ; 75 : 309-12.
13. Wiggers P, Dalhoj J, Kiaer H et al. Screening for haemochromatosis : prevalence among Danish blood donors. J Intern Med 1991 ; 230 : 265-70.
14. Jonsson JJ, Johannesson GM, Sigfusson N, Magnusson B, Thjodleifsson B, Magnusson S. Prevalence of iron deficiency and iron overload in the adult Icelandic population. J Clin Epidemiol 1991 ; 44 : 1289-97.
15. Yaouanq J. Hémochromatose génétique. Etude de prévalence en Bretagne, marqueurs moléculaires associés au gène et leurs applications au conseil génétique. Rennes : Thèse de Doctorat en Sciences Biologiques, 1993 : 151P.
16. Olsson KS, Ritter B, Rosen U, Heedman PA, Staugard F. Prevalence of iron overload in central Sweden. Acta Med Scand 1983 ; 213 : 145-50.
17. Olsson KS, Eriksson K, Ritter B, Heedman PA. Screening for iron overload using transferrin saturation. Acta Med Scand 1984 ; 215 : 105-12.
18. Lindmark B, Eriksson S. Regional differences in the idiopathic hemochromatosis gene frequency in Sweden. Acta Med Scand 1985 ; 218 : 299-304.
19. Elliott R, Tait A, Smith CI, Lin BP, Dent OF. Prevalence of hemochromatosis in a random sample of asymptomatic men. Aust N Z J Med 1986 ; 16 : 491-5.
20. Ballot D, Meyer TE, Bothwell TH et al. Idiopathic hemochromatosis. Family studies and results of a pilot prevalence survey. S Afr Med J 1987 ; 71 : 639-42.
21. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988 ; 318 : 1355-62.
22. Meyer TE, Baynes RD, Bottiwell TH et al. Phenotypic expression of the HLA-linked iron-loading gene in the Afrikaner population of the western Cape. S Afr Med J 1988 ; 73 : 269-74.
23. Hallberg L, Bjorn-Rasmussen E, Jungner I. Prevalence of hereditary haemochromatosis in two Swedish urban areas. J Intern Med 1989 ; 225 : 249-55.
24. Leggett BA, Halliday JW, Brown NN, Bryant S, Powell LW. Prevalence of haemochromatosis amongst asymptomatic Australians. Br J Haematol 1990 ; 74 : 525-30.
25. Gable CB. Hemochromatosis and dietary iron supplementation: implications for US mortality, morbidity, and health survey data. J Am Diet Assoc 1992 ; 92 : 208-12.
26. Porto G, Vicente C, Fraga J, Da Silva BM, de Sousa M, and the Hemochromatosis Clinical and Research Group. Importance of establishing appropriate local reference values for the screening of hemochromatosis: a study of three different control populations and 136 hemochromatosis family members. J Lab Clin Med 1992 ; 119 : 295-305.
27. Balan V, Baldus W, Faibanks V, Michels V, Burritt M, Klee G. Screening for hemochromatosis : a cost - effectiveness study based on 12,258 patients. Gastroenterology 1994 ; 107 : 453-9.
28. Lafraise B, Beranger MF, Mahe J, Verdier JP. Détermination de la prévalence de l'hémochromatose génétique dans la population du centre d'examens de santé de Saint-Nazaire. In : Dépistage de l'hémochromatose génétique dans la population du centre. Années 1990-1991-1992. Saint Nazaire : Centre d'Examens de la CPAM, 1994 : 2-6.
29. Slavin RE. Best evidence synthesis : an intelligent alternative to meta-analysis. J Clin Epidemiol 1995 ; 48 : 9-18.
30. Schoenberg BS. Calculating confidence intervals for rates and ratios. Simplified method utilizing tabular values based on the Poisson distribution. Neuroepidemiology 1983 ; 2 : 257-65.
31. College of American Pathologists. Practice parameter for hereditary hemochromatosis. Draft paper. Northfield, CAP, 1995 ; July : 54P.
32. Borwein S, Ghent CN, Valberg LS. Diagnostic efficacy of screening tests for hereditary hemochromatosis. Can Med Assoc J 1984 ; 131 : 895-901.
33. Milman N. Iron status markers in hereditary haemochromatosis. Distinction between individuals being homozygous and heterozygous for the haemochromatosis allele. Eur J Haematol 1991 ; 47 : 292-8.
34. Halliday JW, Russo AM, Cowlishaw JL, Powell LW. Serum-ferritin in diagnosis of haemochromatosis. A study of 43 families. Lancet 1977 ; 2 : 621-4.
35. Bassett ML, Halliday JW, Ferris RA, Powell LW. Diagnosis of hemochromatosis in young subjects: predictive accuracy of biochemical screening tests. Gastroenterology 1984 ; 87 : 628-33.
36. Valberg LS, Ghent CN, Lloyd DA, Frei JV, Chamberlain MJ. Diagnostic efficacy of tests for the detection of iron overload in chronic liver disease. Can Med Assoc J 1978 ; 119 : 229-36.
37. Wiggers P, Dalhoj J, Hyltoft Petersen P, Blaabjerg O, Horder M. Screening for haemochromatosis: influence of analytical imprecision, diagnostic limit and prevalence on test validity. Scand J Clin Lab Invest 1991 ; 51 : 143-8.
38. Baynes RD, Meyer TE, Bothwell TH, McNamara L. A screening test for detecting iron overload in population studies. S Afr Med J 1988 ; 74 : 167-9.
39. McGill DB, Rakela J, Zinsmeister AR, On BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990 ; 99 : 1396-400.
40. Froehlich F, Lamy O, Fried M, Gonvers JJ. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci 1993 ; 38 : 1480-4.
41. Chuah SY, Moody GA, Wicks ACB, Mayberry JF. A nationwide survey of liver biopsy. Is there a need to increase resources, manpower and training ? Hepatogastroenterology 1994 ; 41 : 4-8.
42. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods and outcomes of percutaneous liver biopsy in England and Wales. An audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995 ; 36 : 437-41.
43. Phatak PD, Guzman G, Woll JE, Rosebon A, Phelps CE. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med 1994 ; 154 : 769-76.
44. Buffone GJ, Beck JR. Cost-effectiveness analysis for evaluation of screening programs : hereditary hemochomatosis. Clin Chem 1994 ; 40 : 1631-6.
45. Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur. Les hémoglobinoses : un problème de santé publique en région Provence-Alpes-Côte d'Azur. Marseille : ORS PACA, 1987, INSERM Unité 240, Le Galès C, Moatti JP Eds.: 11P.
46. Ligue Nationale contre le Cancer. Comment réussir une campagne de dépistage de masse des cancers du sein. Paris : Ligue Nationale contre le Cancer, 1994, avril : 31P.
47. Lamarque JL, Pujol H, Daures JP et al. Contraintes d'un dépistage de masse organisé du cancer du sein. Path Biol 1991 ; 39 : 845.
48. Caisse Primaire d'Assurance Maladie de Saint-Nazaire. Dépistage de l'hémochromatose génétique dans la population du centre. Années 1990-1991-1992. Saint-Nazaire : Centre d'Examens de Santé de la CPAM, 1994.
49. Lancry PJ, Wait S. Analyse économique des dépistages de masse du cancer du sein. A propos de cinq programmes expérimentaux français. Paris : CREDES, 1993: 175P.
50. Mamelle N, Lacour A, Anes A et al. Les expériences de dépistage de masse du cancer du sein par mammographie en France. Un protocole commun d'évaluation. Rev Epidémiol Santé Publique 1994 ; 42 : 34-49.
51. Cairns JA, Shackley PM. The contribution of economics to screening in health care. Eur J Publ Health 1992 ; 2 : 105-12.
52. Conseil d'Evaluation des Technologies de la Santé du Québec. Le dépistage du glaucome primitif à angle ouvert. Montréal : CETS, 1995, février : 101P.
53. Séror V. Economie de la prévention. Exemple du dépistage prénatal. Paris : Ed. INSERM, 1995 : 223P.
54. Cairns J, Shackley P. Sometimes sensitive, seldom specific. A review of the economics of screening. Health Econ 1993 ; 2 : 43-53.
55. Shackley P, McGuire A, Boyd PA et al. An economic appraisal of alternative pre-natal screening programmes for Down's syndrome. J Publ Health Med 1993 ; 15 : 175-84.
56. Darbon S, Letourmy A. La micro-économie des soins médicaux doit-elle nécessairement être d'inspiration néo-classique ? Sci Soc Santé 1983 ; 2 : 31-75.
57. Ausloker J, Ong G. Written information needs of women who are recalled for further investigation of breast screening : results of a multicentre study. J Med Screen 1994 ; 1 : 238-44.
58. Gardent H, Fardeau M, Lanöe JL, Kerleau M. Analyse économique d'une innovation médicale : l'exemple du diagnostic prénatal par amniocentèse précoce. Rev Epidémiol Santé Publique 1984 ; 32 : 97-106.
59. Ornstein SM, Musham C, Reid A, Jenkins RG, Zemp LD, Garr DR. Barriers to adherence to preventive services reminder letters : the patient's perspective. J Fam Pract 1993 ; 36 : 195-200.
60. Lee JM. Screening and informed consent. N Engl J Med 1993 ; 328 : 438-40.
61. Kottke TE, Trapp MA, Fores MM et al. Cancer screening behaviors and attitudes of women in southeastern Minnesota. JAMA 1995 ; 273 : 1099-105.
62. Association Française contre les Myopathies. Génome et Santé. Paris : Ministère du Travail et des Affaires Sociales, mai 1996 : 63P.